Literature DB >> 17635950

The value meal: how to save $1,700 per month or more on lapatinib.

Mark J Ratain1, Ezra E Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17635950     DOI： 10.1200/JCO.2007.12.0758

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

Review 1.  Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors:  Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal:  Mol Oncol       Date:  2012-02-16       Impact factor: 6.603

2.  The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Authors:  Dwight D Kloth; Lew Iacovelli; Rebecca Arbuckle; Angela C McIntosh
Journal:  P T       Date:  2010-04

Review 3.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 4.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Authors:  Joseph M Custodio; Chi-Yuan Wu; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2007-11-28       Impact factor: 15.470

5.  Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.

Authors:  Ahmed Elzawawy
Journal:  Breast Care (Basel)       Date:  2008-11-25       Impact factor: 2.860

6.  Funding a clinical trial: the perspective of a medicines funder.

Authors:  Peter Alsop; Scott Metcalfe; Jackie Evans
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

8.  Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Authors:  Shirish M Gadgeel; Danika L Lew; Timothy W Synold; Patricia LoRusso; Vincent Chung; Scott D Christensen; David C Smith; Laura Kingsbury; Antje Hoering; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-22       Impact factor: 3.333

9.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

10.  The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.

Authors:  Ahmed Elzawawy
Journal:  World J Surg Oncol       Date:  2009-05-05       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.